MediWound (MDWD) delivered earnings and revenue surprises of -8.33% and 32.86%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, NY / ACCESSWIRE / May 20, 2020 / MediWound Ltd. (NASDAQ:MDWD) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 20, 2020 at 8:30 AM Eastern ...

YAVNE, Israel, May 20, 2020 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs.

MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agreement with GENFA MEDICA SA, granting it the exclusive right to market and distribute NexoBrid® in Ukraine, Lithuania, Latvia and Estonia adding to its current rights to distribute NexoBrid in Russia.

YAVNE, Israel, May 13, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.

Q4 2019 Mediwound Ltd Earnings Call

MediWound Ltd. (MDWD) and its U.S. commercial partner Vericel Corporation (VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary for Preparedness and Response (ASPR), a part of the U.S. Department of Health and Human Services (HHS), has begun procuring NexoBrid® for emergency stockpile as part of the HHS mission to build national preparedness for public health medical emergencies. BARDA purchased inventory will be managed by MediWound under vendor managed inventory. The initial BARDA procurement is valued at $16.5 million, with the first delivery of NexoBrid expected by the end of the first quarter of 2020 and additional deliveries occurring over the subsequent five quarters.

MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointments of Mr. Samuel Moed and Mr. David Fox to its Board of Directors to serve until the 2020 annual meeting of shareholders. Stephen T. Wills, MediWound’s Chairman since 2018, was named Executive Chairman.

Investors always look for companies with a high level of profitability regardless of the present market condition.

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has expanded its awarded contract with MediWound providing supplemental funding of $5.5 million to support emergency readiness for NexoBrid deployment upon request of use of NexoBrid in mass casualty situation.

MediWound Ltd. (MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19 pandemic on its business operations and clinical programs. At the same time, the Company is working to ensure that healthcare providers and patients have uninterrupted access to our commercial and products under development. The Company has instituted a global remote work policy and is now leveraging virtual tools and digital communication technologies to continue important interactions with its employees, healthcare professionals, patients and other stakeholders.

MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design.

YAVNE, Israel, Feb. 18, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.

Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers

It is hard to get excited after looking at MediWound's (NASDAQ:MDWD) recent performance, when its stock has declined...

Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 40.00% over the past year to ($0.09), which beat the estimate of ($0.14).Revenue of $4,438,000 up by 862.69% year over year, which beat the estimate of $4,050,000.Outlook MediWound hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 20, 2020View more earnings on MDWDTime: 08:30 AMET Webcast URL: https://mediwound.gcs-web.com/events-and-presentationsRecent Stock Performance 52-week high: $4.6552-week low: $1.44Price action over last quarter: down 13.33%Company Overview MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from United States.See more from Benzinga * McKesson: Q4 Earnings Insights * Recap: Lowe's Companies Q1 Earnings * ShiftPixy: P/E Ratio Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

YAVNE, Israel, Feb. 28, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.

MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus. NexoBrid, currently approved in the European Union and other international markets, is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns.